Blood Cancer Journal

Papers
(The H4-Index of Blood Cancer Journal is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
CAR-T cell therapy: current limitations and potential strategies886
Acute myeloid leukemia: current progress and future directions310
Multiple myeloma current treatment algorithms177
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma132
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)124
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple m122
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies100
New directions for emerging therapies in acute myeloid leukemia: the next chapter96
CAR T-cell therapy in multiple myeloma: more room for improvement95
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment95
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia93
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study88
Acute promyelocytic leukemia current treatment algorithms79
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report78
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia78
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups77
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies74
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm74
Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century68
Chromosome 1q21 abnormalities in multiple myeloma65
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma65
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage63
The high cost of prescription drugs: causes and solutions63
Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study62
FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm62
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma61
Extramedullary disease in multiple myeloma: a systematic literature review58
Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response57
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality53
Core binding factor acute myelogenous leukemia-2021 treatment algorithm50
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up 50
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis49
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab49
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)48
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy47
Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study47
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis46
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma45
Genetic and epigenetic determinants of diffuse large B-cell lymphoma45
AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia44
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life44
Extramedullary disease in multiple myeloma43
DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies43
0.026733160018921